Clinical trials: Chemotherapeutic Toxicity
Radiation Therapy Complication, Chemotherapeutic Toxicity
System for High-Intensity Evaluation During Radiotherapy
This quality improvement project will evaluate the implementation of a previously described intervention (twice per week on-treatment clinical evaluations) in a feasible fashion using a previously described machine learning…
- Trial name
- SHIELD-RT (NCT04277650)
- Testing
- Machine learning algorithm
- Where
- United States
- Volunteers
- 311 people
- Sponsor
- Duke University
Breast Cancer, Cardiotoxicity
Understanding CARdiac Events in Breast Cancer
In Ireland, over 3,000 patients are diagnosed with breast cancer annually, and 1 in 9 Irish women will be diagnosed with breast cancer in their lifetime.
- Conditions
- Breast Cancer, Cardiotoxicity, Cardiomyopathies, Chemotherapeutic Toxicity
- Trial name
- UCARE (NCT05921279)
- Where
- 4 sites in Ireland
- Volunteers
- 100 people
- Sponsor
- National University of Ireland, Galway, Ireland
Chemotherapeutic Agent Toxicity, Sarcoma
CYP3A5 Gene as a Risk Factor for Kidney Damage in Young Patients With Cancer Treated With Ifosfamide
RATIONALE: Studying the genes expressed in samples of blood from young patients with cancer treated with ifosfamide may help doctors identify risk factors for kidney damage.
- Conditions
- Chemotherapeutic Agent Toxicity, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00514345
- Testing
- gene expression analysis, polymorphism analysis, management of therapy complications
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 300 people
- Sponsor
- Children's Cancer and Leukaemia Group
Chemotherapeutic Agent Toxicity, Neutropenia
G-CSF in Preventing Neutropenia in Patients With Solid Tumors Who Are Receiving Chemotherapy
RATIONALE: Colony-stimulating factors, such as G-CSF, may increase the number of white blood cells found in bone marrow or peripheral blood and may prevent persistent neutropenia in patients receiving chemotherapy.
- Conditions
- Chemotherapeutic Agent Toxicity, Neutropenia, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00770172
- Testing
- filgrastim
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Centre Francois Baclesse
Dermatologic Complications, Palmar-plantar Erythrodysesthesia
Pyridoxine in Preventing Hand-Foot Syndrome Caused by Capecitabine in Patients With Cancer
RATIONALE: Pyridoxine may help prevent hand-foot syndrome caused by capecitabine in patients with cancer. It is not yet known whether pyridoxine is more effective than a placebo in preventing hand-foot syndrome in patients with…
- Conditions
- Dermatologic Complications, Palmar-plantar Erythrodysesthesia, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00486213
- Testing
- pyridoxine hydrochloride
- Where
- Singapore
- Volunteers
- 210 people
- Sponsor
- National Cancer Centre, Singapore
Myocardial Fibrosis, Myocardial Injury
Myocardial Perfusion and Fibrosis in Cancer Survivors
This is a cross-sectional pilot study. The investigators seek to obtain early information pertaining to the relationship between measurements of myocardial perfusion reserve and myocardial fibrosis after receipt of…
- Conditions
- Myocardial Fibrosis, Myocardial Injury, Chemotherapeutic Toxicity
- Trial name
- NCT03191461
- Testing
- Adenosine stress test MRI
- Where
- 2 sites in United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Cancer, Chemotherapeutic Toxicity
Serial PET MPI in Patients Undergoing Cancer Treatment
This study aims to evaluate the effects of cardiotoxic cancer therapies on myocardial blood flow (MBF) and perfusion in a prospective sample of VA patients.
- Conditions
- Cancer, Chemotherapeutic Toxicity, Coronary Artery Disease, Coronary Microvascular Disease
- Trial name
- NCT05913999
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, Los Angeles
Myelosuppression Adult, Chemotherapeutic Toxicity
Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer
The purpose of this expanded access protocol is to provide access to trilaciclib for chemotherapy-induced myelosuppression in patients receiving chemotherapy as a treatment for small cell lung cancer (SCLC).
- Conditions
- Myelosuppression Adult, Chemotherapeutic Toxicity, Small Cell Lung Cancer
- Trial name
- NCT04504513
- Testing
- Trilaciclib
- Sponsor
- G1 Therapeutics, Inc.
Mucositis, Chemotherapeutic Toxicity
The Efficacy and Safety of a Compound Glutamine Capsule in the Primary Prevention of Chemotherapy-induced Mucositis
Chemotherapy regimens not only improve the survival of patients with gastric cancer and colorectal cancer, but also cause obvious adverse reactions of digestive tract, such as chemotherapy-induced oral mucositis, abdominal pain…
- Trial name
- NCT05092113
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Meng Qiu
Chemotherapeutic Toxicity
Residual Neuromuscular Block of Rocuronium in Chemotherapy Patients Under Sevoflurane Anesthesia
Chemotherapy causes motor nerve dysfunction and degeneration that may alter the response to neuromuscular blocking drugs. To analyse the risk of residual neuromuscular block (RNMB) induced by rocuronium given in standard doses to…
- Trial name
- NCT04965532
- Testing
- sevoflurane anesthesia, Propofol Injection
- Where
- 2 sites in China
- Volunteers
- 80 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Oral Mucositis, Quality of Life
Retrospective Observational Study of Oral Complications and Quality of Life in Head and Neck Cancer Patients Treated With Radiotherapy or Chemoradiotherapy.
Head and Neck cancer patients receiving radiation therapy (with or without chemotherapy) suffer several oral complications, such as oral mucositis, which impairs quality of life of patients during radiotherapy and in the…
- Conditions
- Oral Mucositis, Quality of Life, Mucositis, Pain
- Trial name
- NCT07739771
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Mucosa Innovations, S.L.
Breast Neoplasms, Cardiac Event
Clinical Study of Xinmailong Injection on Reducing Cardiovascular Toxicity in Adjuvant Chemotherapy in Breast Cancer
Totally 60 subjects will be included in the study. The present study was aimed to observe and evaluate the effect of Xinmailong injection on reducing cardiovascular toxicity associated with adjuvant chemotherapy after breast…
- Conditions
- Breast Neoplasms, Cardiac Event, Chemotherapeutic Toxicity
- Trial name
- NCT03785704
- Testing
- Xinmailong Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College
Chemotherapeutic Agent Toxicity, Renal Toxicity
Kidney Damage in Patients Receiving Cisplatin and Ifosfamide for Solid Tumors
RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Conditions
- Chemotherapeutic Agent Toxicity, Renal Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00695032
- Testing
- cisplatin, ifosfamide, laboratory biomarker analysis
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Institut Claudius Regaud
Invasive Breast Cancer, Chemotherapeutic Toxicity
Prophylactic Gabapentin for Taxane-Induced Arthralgia and Myalgia Syndrome in Breast Cancer Patients Undergoing Adjuvant Chemotherapy
Taxane-induced arthralgia and myalgia syndrome (TAMS) is one of the most common side effects of taxane chemotherapy. This prospective randomized controlled trial will evaluate the efficacy of gabapentin administered…
- Conditions
- Invasive Breast Cancer, Chemotherapeutic Toxicity, Myalgia, Arthralgia
- Trial name
- NCT03566394
- Testing
- Gabapentin 300mg
- Volunteers
- 46 people
- Sponsor
- British Columbia Cancer Agency
Chemotherapeutic Agent Toxicity, Multiple Myeloma
Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib
This randomized phase II trial studies glutamine in preventing peripheral neuropathy in patients with multiple myeloma who are receiving bortezomib.
- Conditions
- Chemotherapeutic Agent Toxicity, Multiple Myeloma, Peripheral Neuropathy
- Trial name
- NCT01783522
- Testing
- glutamine, quality-of-life assessment
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Beth Faiman
Thrombopenia, Cervical Cancer
Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer
Exploring and evaluating the efficacy of herombopag in preventing thrombocytopenia due to radiotherapy for cervical cancer
- Conditions
- Thrombopenia, Cervical Cancer, Radiotherapy Side Effect, Chemotherapeutic Toxicity
- Trial name
- NCT06745219
- Testing
- herombopag
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Chemotherapeutic Agent Toxicity, Neuropathy
Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
This randomized phase III trial is studying glutathione to see how well it works in preventing peripheral neuropathy caused by paclitaxel and carboplatin in patients with ovarian cancer, fallopian tube cancer, and/or primary…
- Conditions
- Chemotherapeutic Agent Toxicity, Neuropathy, Neurotoxicity Syndrome, Pain
- Trial name
- NCT02311907
- Testing
- Carboplatin, Glutathione, Laboratory Biomarker Analysis
- Where
- 390 sites in United States
- Volunteers
- 195 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cancer, Chemotherapeutic Toxicity
Effectiveness of Mobile Based Monitoring System in the Management of Chemotherapy-Related Symptoms
Mobile health applications open the door to a safe and effective health system. Mobile communication channels and mobile phones not only provide training paths to healthcare professionals, but also provide remote decision support…
- Conditions
- Cancer, Chemotherapeutic Toxicity, Mobile Applications
- Trial name
- NCT05946070
- Testing
- ONKOSIS
- Where
- Turkey (Türkiye)
- Volunteers
- 199 people
- Sponsor
- Istanbul University - Cerrahpasa
Malignant Pleural Effusion, Pleural Neoplasms
OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.
This study will monitor and evaluate patient and personnel safety and toxicity during the implementation and evaluation of Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) directed treatment.
- Conditions
- Malignant Pleural Effusion, Pleural Neoplasms, Quality of Life, Chemotherapy Effect
- Trial name
- NCT06421610
- Testing
- PITAC
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Odense University Hospital
Chemotherapeutic Agent Toxicity, Colorectal Cancer
Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin
RATIONALE: Studying samples of blood in the laboratory from patients receiving oxaliplatin for cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to neurotoxicity.
- Conditions
- Chemotherapeutic Agent Toxicity, Colorectal Cancer, Neurotoxicity
- Trial name
- NCT00884767
- Testing
- FOLFOX regimen, fluorouracil, leucovorin calcium
- Where
- France
- Volunteers
- 206 people
- Sponsor
- Institut Cancerologie de l'Ouest